Original ArticlesPropranolol for Surgeons in the Treatment of Infantile HemangiomasSinha, Shiba MBBS, MRCS(Eng); Lloyd, Mark Sheldon MPhil, FRCS(Plast)Author Information Birmingham Children's Hospital, Birmingham, United Kingdom. Address correspondence and reprint requests to Mark Sheldon Lloyd, MPhil, FRCS (Plast), Birmingham Children's Hospital, 01213339999, United Kingdom; E-mail: email@example.com Received 25 June, 2019 Accepted 15 July, 2019 The authors report no conflicts of interest. Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcraniofacialsurgery.com). Journal of Craniofacial Surgery: January/February 2020 - Volume 31 - Issue 1 - p 134-137 doi: 10.1097/SCS.0000000000005919 Buy SDC Metrics Abstract Introduction: Beta-blocker (Propanolol or Timolol maleate) treatment of infantile hemangiomas (IH) is a safe and effective treatment in the outpatient setting. The authors report a single surgeon's initial experience with setting up an outpatient service of beta-blocker treatment for head and neck IH at a tertiary children's hospital. Methods: A prospective study of children with head and neck IHs commenced in January 2015 with the end point being December 2018. Each child started either oral propranolol (2 mg/kg/day) or topical Timolol 0.5%. Results: Thirty-eight patients commenced a beta-blocker during the study duration. The mean age at time of starting therapy was 9 months (range 3 weeks to 116 months). Four patients were older than 12 months at commencement. The mean duration of treatment was 9 months. The response to treatment was excellent or complete in 29% (n = 11), good in 50% (n = 18) and mild in 10% (n = 4). The non response rate was 10% (n = 4). No major adverse effects occurred but 29% (n = 11) experienced minor side effects. Conclusion: Low dose propranolol and topical Timolol is been safe and easy to use for surgeons who may not be regular prescribers or unfamiliar with treating children with IHs with beta-blocker therapy. In patient monitoring is unnecessary and parents can be taught easily to recognise side effects. Treating children from the start builds a trusting relationship with the family before the child requesting cosmetic revision of the fibro-fatty remnant. © 2020 by Mutaz B. Habal, MD.